arrow
S

Suzanne Carreira

The Institute of Cancer Research
H指数:49
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

一项开放标签、I期剂量探索研究,评估单药IMU-935(一种新型RORγ/RORγt反向激动剂)在进展性转移性去势抵抗性前列腺癌患者中的疗效。

2026-03-110
OAAI
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Capivasertib联合恩扎鲁他胺治疗多西他赛和阿比曲酮治疗转移性去势抵抗性前列腺癌: 随机II期RE-AKT试验的结果

2024-07-011
OAAI
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024-02-272
OAAI
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

靶向髓系趋化逆转前列腺癌治疗耐药

Nature
IF48.5
2023-10-160
OAAI
Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
2023-10-010
OA
BCL2 expression is enriched in AR-independent advanced prostate cancer
2023-06-021
PRE
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer (vol 83, pg 224, 2023)

B7-H3作为晚期前列腺癌的治疗靶点 (第83卷,224页,2023页)

2023-06-011
OA
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

转移性去势抵抗性前列腺癌的免疫标志物

2022-12-0114
PRE
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

guadecitabine (SGI-110) 联合pembrolizumab治疗实体瘤患者的1期剂量递增研究

2022-06-1826
OAAI